Article
Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
Histopathology - 1 Nov 2014
Preusser Matthias, Streubel Berthold, Berghoff Anna S, Hainfellner Johannes A, von Deimling Andreas, Widhalm Georg, Dieckmann Karin, Wöhrer Adelheid, Hackl Monika, Zielinski Christoph, Birner Peter
Abstract excerpt
BACKGROUND: CMET represents an emerging therapy target for monoclonal antibodies and tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). METHODS: We investigated CMET gene amplification status by fluorescence in-situ hybridization (FISH) and CMET protein expression by immunohistochemistry in a large series of 209 NSCLC brain metastases (BM; 165 adenocarcinoma, 20 squamous cell carcinoma, 11...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.